Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Observationsstatusen för Recipharm AB (publ) uppdateras/The observation status for Recipharm AB (publ) is updated (21/21)

Read the release
Nasdaq Stockholm AB
Equity Market information

Observationsstatusen för Recipharm AB (publ) uppdateras/The observation status
for Recipharm AB (publ) is updated (21/21)

Den 14 december 2020 gavs aktierna i Recipharm AB (publ) (”Recipharm” eller
”Bolaget”) observationsstatus med hänvisning till ett offentligt
uppköpserbjudande från EQT IX, genom Roar BidCo AB (”Roar BidCo”), till
aktieägarna i Bolaget. 

Den 15 februari 2021 offentliggjorde Recipharm ett pressmeddelande med
information om att Roar BidCo kontrollerar ca 95,1 procent av aktierna i
Recipharm och har påkallat tvångsinlösen av resterande aktier i Bolaget.
Recipharm meddelade vidare att Bolaget, på begäran av Roar BidCo, ansökt om
avnotering av dess aktier från Nasdaq Stockholm. 

Enligt gällande regelverk för Nasdaq Stockholm kan en emittents finansiella
instrument ges observationsstatus om emittenten ansökt om avnotering av dessa. 

Med ovanstående bakgrund beslutar Börsen att uppdatera observationsstatusen för
aktierna i Recipharm AB (publ) (RECI B, ISIN-kod SE0005757267, orderboks-ID
100208). 



On December 14, 2020, the shares in Recipharm AB (publ) (“Recipharm” or the
“Company”) were given observation status with reference to a takeover bid from
EQT IX, through Roar BidCo AB (“Roar BidCo”), to the shareholders of the
Company. 

On February 15, 2021, Recipharm disclosed a press release with information that
Roar BidCo controls approximately 95.1 per cent of the shares in Recipharm and
has initiated a compulsory redemption of the remaining shares in the Company.
Recipharm also informed that the Company, at the request of Roar BidCo, had
applied for delisting of its shares from Nasdaq Stockholm. 

The rules of Nasdaq Stockholm state that an issuer’s financial instruments may
be given observation status if the issuer has applied to have them removed from
trading. 

With reference to the above, the Exchange decides to update the observation
status of the shares in Recipharm AB (publ) (RECI B, ISIN code SE0005757267,
order book ID 100208). 



För eventuella frågor om detta börsmeddelande vänligen kontakta
Bolagsövervakningen på telefon 08-405 70 50. 

For further information concerning this exchange notice please contact Issuer
Surveillance, telephone + 46 8 405 70 50. 





Nasdaq Stockholm AB
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team